metastatic castration-resistant prostate cancer

4 · 20 / page

Ask MedXY AI

Latest news

Tag

news177Lu-PSMA-617mCRPC

Baseline PSMA Total Tumor Volume Predicts Who Benefits from Adding 177Lu‑PSMA‑617 to Enzalutamide in First‑line mCRPC

By MedXY|Nov 5, 2025

In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.

news177Lu-PSMAmCRPC

Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra

metastatic castration-resistant prostate cancer

Latest news

Baseline PSMA Total Tumor Volume Predicts Who Benefits from Adding 177Lu‑PSMA‑617 to Enzalutamide in First‑line mCRPC

Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra

Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223